Cartography Biosciences: $67 Million Series B Closed For Advancing Novel Antibody-Based Oncology Therapies
By Amit Chowdhry ● Oct 17, 2025
Cartography Biosciences, Inc., a precision oncology company developing next-generation T-cell engaging antibody therapeutics, announced it has closed a $67 million Series B financing to accelerate its differentiated pipeline toward the clinic. The round was led by Pfizer Ventures, with participation from new investors LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, and Lotte Holdings CVC, alongside existing backers Andreessen Horowitz (a16z) Bio + Health, 8VC, Wing Venture Capital, Catalio Capital Management, AME Cloud Ventures, ARTIS Ventures, and Gaingels.